while in the speedily evolving subject of oncology investigate, precise and economical mutation screening is vital for building focused therapies. The KRAS companies Platform plays a pivotal purpose On this landscape by offering thorough options for KRAS mutation profiling and Evaluation. KRAS mutations, present in approximately ninety five% of RAS